PSCs have the ability to differentiate into any of the 220+ cell types found in the human body. This capability provides great potential for cell therapies, with a growing range of clinical applications.

Induced PSCs (iPSCs) can be generated by expressing specific transcription factor(s) in primary somatic cells, reverting the cells back into a pluripotent state.

We are firm believers of the potential of iPSC based therapies and have invested significant efforts and resources in enabling the manufacturing of cGMP grade materials derived iPSCs for our customers today and tomorrow.


See the opportunity in every challenge

iPSC challenges.png

We can help you address your key challenges in iPSC manufacturing and convert them into opportunities. Whether it is iPSC reprogramming or differentiation under cGMP, process control and characterization or efficient scale-up, we have a tailored solution.

 

Leverage established cGMP-grade iPSC capabilities

As the manufacturers of the world’s first reported GMP iPSC bank, we have extensive experience in cGMP pluripotent stem cell generation and banking.

We provide a full range of iPSC manufacturing services tailored to your needs, to help you achieve scalable production in a cGMP setting.

iPSC capabilities.png

We have the expertise to reprogram many different cell types such as human peripheral blood mononuclear cells (PBMCs), dermal fibroblasts, CD34+ hematopoietic progenitors and T cells.


Rely on an established process

L7_Illustration_adjusted_2000-1210.jpg

Non-viral 4D-Nucleofector™ Transfection Technology is a key integral part for the reprogramming of cGMP grade iPSCs. With our cGMP iPSC manufacturing platform using the L7 cell culture system, you can rely on a proven, established process.

 

Perform directed differentiation into all three lineages

directeddifferenciation.png

We have successfully generated specialized cells from human pluripotent stem cells in both standard 2D cell culture system and in a computer-controlled 3D bioreactor.  

 

What can this do for you?

iPSC solutions.png

 

So why choose our iPSC services?

  • World’s first iPSC GMP bank (2014) NIH
  • Master File readily available for cross reference with any sponsor’s filing
  • 8+ years of iPSC expertise, including research and development
  • Key opinion leadership through publications on iPSC manufacturing and characterization
  • E2E service offering
  • Phase appropriate assay and process development and qualification
  • Tissue acquisition
  • PSC reprogramming, expansion and differentiation (2D cell culture system and 3D computer-controlled bioreactors)
  • Fill & finish
  • Supply chain orchestration system through partnerships
  • Multiple cGMP customers working with PSC and iPSC cells
  • Proprietary L7 GMP platform services to enhance robustness
  • R&D team focused on further developing next generation GMP technologies

 

Download our latest iPSC platform literature

Human-Induced Pluripotent Stem Cells Manufactured Using a Current Good Manufacturing Practice-Compliant Process Differentiate Into Clinically Relevant Cells From Three Germ Layers – March 2018
Request PDF

Computational Fluid Dynamics Modeling, a Novel, and Effective Approach for Developing Scalable Cell Therapy Manufacturing Processes

Request PDF

Use the form below to schedule a meeting with our iPSCs manufacturing experts.

 

By submitting your data through this form, you confirm that you are above the age of 18, that you have read and understood the Privacy Policy, and that you agree to the collection, use and processing of your Personal Information by Lonza in accordance with said policy.

Legal Disclaimer

Lonza provides the information contained herein “as-is” and without warranty, either express or implied. Customers are encouraged to consider intellectual property rights associated with iPSC processes on their own and Lonza makes no representations or warranties as to whether a particular process, method, or product described herein infringes others’ intellectual property.